Beyond tobacco: genomic disparities in lung cancer between smokers and never-smokers.
Cancer disparities
Chilean
EGFR mutation
KRAS
Latin American populations
Lung Adenocarcinoma
MAP2K1
Tobacco consumption
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
03 Aug 2024
03 Aug 2024
Historique:
received:
18
02
2024
accepted:
31
07
2024
medline:
4
8
2024
pubmed:
4
8
2024
entrez:
3
8
2024
Statut:
epublish
Résumé
Tobacco use is one of the main risk factors for Lung Cancer (LC) development. However, about 10-20% of those diagnosed with the disease are never-smokers. For Non-Small Cell Lung Cancer (NSCLC) there are clear differences in both the clinical presentation and the tumor genomic profiles between smokers and never-smokers. For example, the Lung Adenocarcinoma (LUAD) histological subtype in never-smokers is predominately found in young women of European, North American, and Asian descent. While the clinical presentation and tumor genomic profiles of smokers have been widely examined, never-smokers are usually underrepresented, especially those of a Latin American (LA) background. In this work, we characterize, for the first time, the difference in the genomic profiles between smokers and never-smokers LC patients from Chile. We conduct a comparison by smoking status in the frequencies of genomic alterations (GAs) including somatic mutations and structural variants (fusions) in a total of 10 clinically relevant genes, including the eight most common actionable genes for LC (EGFR, KRAS, ALK, MET, BRAF, RET, ERBB2, and ROS1) and two established driver genes for malignancies other than LC (PIK3CA and MAP2K1). Study participants were grouped as either smokers (current and former, n = 473) or never-smokers (n = 200) according to self-report tobacco use at enrollment. Our findings indicate a higher overall GA frequency for never-smokers compared to smokers (58 vs. 45.7, p-value < 0.01) with the genes EGFR, KRAS, and PIK3CA displaying the highest prevalence while ERBB2, RET, and ROS1 the lowest. Never-smokers present higher frequencies in seven out of the 10 genes; however, smokers harbor a more complex genomic profile. The clearest differences between groups are seen for EGFR (15.6 vs. 21.5, p-value: < 0.01), PIK3CA (6.8 vs 9.5) and ALK (3.2 vs 7.5) in favor of never-smokers, and KRAS (16.3 vs. 11.5) and MAP2K1 (6.6 vs. 3.5) in favor of smokers. Alterations in these genes are comprised almost exclusively by somatic mutations in EGFR and mainly by fusions in ALK, and only by mutations in PIK3CA, KRAS and MAP2K1. We found clear differences in the genomic landscape by smoking status in LUAD patients from Chile, with potential implications for clinical management in these limited-resource settings.
Sections du résumé
BACKGROUND
BACKGROUND
Tobacco use is one of the main risk factors for Lung Cancer (LC) development. However, about 10-20% of those diagnosed with the disease are never-smokers. For Non-Small Cell Lung Cancer (NSCLC) there are clear differences in both the clinical presentation and the tumor genomic profiles between smokers and never-smokers. For example, the Lung Adenocarcinoma (LUAD) histological subtype in never-smokers is predominately found in young women of European, North American, and Asian descent. While the clinical presentation and tumor genomic profiles of smokers have been widely examined, never-smokers are usually underrepresented, especially those of a Latin American (LA) background. In this work, we characterize, for the first time, the difference in the genomic profiles between smokers and never-smokers LC patients from Chile.
METHODS
METHODS
We conduct a comparison by smoking status in the frequencies of genomic alterations (GAs) including somatic mutations and structural variants (fusions) in a total of 10 clinically relevant genes, including the eight most common actionable genes for LC (EGFR, KRAS, ALK, MET, BRAF, RET, ERBB2, and ROS1) and two established driver genes for malignancies other than LC (PIK3CA and MAP2K1). Study participants were grouped as either smokers (current and former, n = 473) or never-smokers (n = 200) according to self-report tobacco use at enrollment.
RESULTS
RESULTS
Our findings indicate a higher overall GA frequency for never-smokers compared to smokers (58 vs. 45.7, p-value < 0.01) with the genes EGFR, KRAS, and PIK3CA displaying the highest prevalence while ERBB2, RET, and ROS1 the lowest. Never-smokers present higher frequencies in seven out of the 10 genes; however, smokers harbor a more complex genomic profile. The clearest differences between groups are seen for EGFR (15.6 vs. 21.5, p-value: < 0.01), PIK3CA (6.8 vs 9.5) and ALK (3.2 vs 7.5) in favor of never-smokers, and KRAS (16.3 vs. 11.5) and MAP2K1 (6.6 vs. 3.5) in favor of smokers. Alterations in these genes are comprised almost exclusively by somatic mutations in EGFR and mainly by fusions in ALK, and only by mutations in PIK3CA, KRAS and MAP2K1.
CONCLUSIONS
CONCLUSIONS
We found clear differences in the genomic landscape by smoking status in LUAD patients from Chile, with potential implications for clinical management in these limited-resource settings.
Identifiants
pubmed: 39097719
doi: 10.1186/s12885-024-12737-1
pii: 10.1186/s12885-024-12737-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
951Informations de copyright
© 2024. The Author(s).
Références
Piñeros M, Laversanne M, Barrios E, de Camargo Cancela M, de Vries E, Pardo C, Bray F. An updated profile of the cancer burden, patterns and trends in Latin America and the caribbean. Lancet Reg Health Am. 2022;13:1–14. https://doi.org/10.1016/j.lana.2022.100294 .
doi: 10.1016/j.lana.2022.100294
Wakelee HA, Chang ET, Gomez SL, Keegan THM, Feskanich D, Clarke CA, Holmberg L, Yong LC, Kolonel LN, Gould MK, et al. Lung cancer incidence in never-smokers. J Clin Oncol. 2007;25:472–8. https://doi.org/10.1200/JCO.2006.07.2983 .
doi: 10.1200/JCO.2006.07.2983
pubmed: 17290054
Field RW, Withers BL. Occupational and environmental causes of lung cancer. Clin Chest Med. 2012;33:681–703. https://doi.org/10.1016/j.ccm.2012.07.001 .
doi: 10.1016/j.ccm.2012.07.001
pubmed: 23153609
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30. https://doi.org/10.3322/caac.21590 .
doi: 10.3322/caac.21590
pubmed: 31912902
Pinheiro PS, Callahan KE, Medina HN, Koru-Sengul T, Kobetz EN, Gomez SL, de Lima Lopes G. Lung cancer in never smokers: distinct population-based patterns by age, sex, and race/ethnicity. Lung Cancer. 2022;174:50–6. https://doi.org/10.1016/j.lungcan.2022.10.009 .
doi: 10.1016/j.lungcan.2022.10.009
pubmed: 36334356
Clément-Duchêne C, Vignaud JM, Stoufflet A, Bertrand O, Gislard A, Thiberville L, Grosdidier G, Martinet Y, Benichou J, Hainaut P, et al. Characteristics of never smoker lung cancer including environmental and occupational risk factors. Lung Cancer. 2010;67:144–50. https://doi.org/10.1016/j.lungcan.2009.04.005 .
doi: 10.1016/j.lungcan.2009.04.005
pubmed: 19464070
Boeckx B, Shahi RB, Smeets D, De Brakeleer S, Decoster L, Van Brussel T, Galdermans D, Vercauter P, Decoster L, Alexander P, et al. The genomic landscape of nonsmall cell lung carcinoma in never smokers. Int J Cancer. 2020;146:3207–18. https://doi.org/10.1002/ijc.32797 .
doi: 10.1002/ijc.32797
pubmed: 31745979
Clément-Duchêne C, Stock S, Xu X, Chang ET, Gomez SL, West DW, Wakelee HA, Gould MK. Survival among never-smokers with lung cancer in the cancer care outcomes research and surveillance study. Ann Am Thorac Soc. 2016;13:58–66. https://doi.org/10.1513/AnnalsATS.201504-241OC .
doi: 10.1513/AnnalsATS.201504-241OC
pubmed: 26730864
pmcid: 5461981
Chapman AM, Sun KY, Ruestow P, Cowan DM, Madl AK. Lung cancer mutation profile of EGFR, ALK, and KRAS: meta-analysis and comparison of never and ever smokers. Lung Cancer. 2016;102:122–34. https://doi.org/10.1016/j.lungcan.2016.10.010 .
doi: 10.1016/j.lungcan.2016.10.010
pubmed: 27987580
Barlesi F, Mazières J, Merlio J, Debieuvre D, Léna H, Ouafik H, Besse B, Rouquette I, Westeel V. Routine molecular profiling of cancer : results of a one-year nationwide program of the french cooperative thoracic intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients. Lancet. 2016;287:1415–26. https://doi.org/10.1016/S0140-6736(16)00004-0 .
doi: 10.1016/S0140-6736(16)00004-0
Zhu Q, Zhan P, Zhang X, Lv T, Song Y. Clinicopathologic characteristics of patients with ROS1 fusion gene in non-small cell lung cancer: a meta-analysis. Transl Lung Cancer Res. 2015;4:300–9. https://doi.org/10.3978/j.issn.2218-6751.2015.05.01 .
doi: 10.3978/j.issn.2218-6751.2015.05.01
pubmed: 26207220
pmcid: 4483477
Okudela K, Matsumura M, Arai H, Woo T. The nonsmokers’ and smokers’ pathways in lung adenocarcinoma: histological progression and molecular bases. Cancer Sci. 2021;112:3411–8. https://doi.org/10.1111/cas.15031 .
doi: 10.1111/cas.15031
pubmed: 34143937
pmcid: 8409399
Arcila ME, Drilon A, Sylvester BE, Lovly CM, Borsu L, Reva B, Kris MG, Solit DB, Ladanyi M. MAP2K1 (MEK1) Mutations define a distinct subset of lung adenocarcinoma associated with smoking. Clin Cancer Res. 2015;21:1935–43. https://doi.org/10.1158/1078-0432.CCR-14-2124 .
doi: 10.1158/1078-0432.CCR-14-2124
pubmed: 25351745
Rojas Hitschfeld HA. Análisis epidemiológico: mortalidad por cáncer de pulmón e indicadores de consumo de cigarrillo en Chile. Revista Instituto Salud Pública Chile. 2021;5:21–7. https://doi.org/10.34052/rispch.v5i2.145 .
doi: 10.34052/rispch.v5i2.145
Martinez VD, Vucic EA, Lam S, Lam WL. Arsenic and lung cancer in never-smokers: lessons from Chile. Am J Respir Crit Care Med. 2012;185:1131–2. https://doi.org/10.1164/ajrccm.185.10.1131 .
doi: 10.1164/ajrccm.185.10.1131
pubmed: 22589318
Burotto M, Aren O, Renner A, Samtani S, de la Jara JJ. Lung cancer in Chile. J Thorac Oncol. 2019;14:1504–9. https://doi.org/10.1016/j.jtho.2019.02.024 .
doi: 10.1016/j.jtho.2019.02.024
pubmed: 31445729
Gimbrone NT, Sarcar B, Gordian ER, Rivera JI, Lopez C, Yoder SJ, Teer JK, Welsh EA, Chiappori AA, Schabath MB, et al. Brief report: somatic mutations and ancestry markers in hispanic lung cancer patients. J Thoracic Oncol. 2017;12:1851–6. https://doi.org/10.1016/J.JTHO.2017.08.019 .
doi: 10.1016/J.JTHO.2017.08.019
Carrot-Zhang J, Soca-Chafre G, Patterson N, Thorner AR, Nag A, Watson J, Genovese G, Rodriguez J, Gelbard MK, Corrales-Rodriguez L, et al. Genetic ancestry contributes to somatic mutations in lung cancers from admixed Latin American populations. Cancer Discov. 2021;11:591–8. https://doi.org/10.1158/2159-8290.CD-20-1165/333527/AM/GENETIC-ANCESTRY-CONTRIBUTES-TO-SOMATIC-MUTATIONS .
doi: 10.1158/2159-8290.CD-20-1165/333527/AM/GENETIC-ANCESTRY-CONTRIBUTES-TO-SOMATIC-MUTATIONS
pubmed: 33268447
Cardona AF, Arrieta-Mercado O, Ruíz-Patiño A, Rojas L, Rolfo C. Características de los pacientes con cancer de pulmon de celula no pequeña en el instituto nacional de cancerología de Colombia. Rev Colomb Cancerol. 2021;25:226–31. https://doi.org/10.35509/01239015.815 .
doi: 10.35509/01239015.815
Parra-Medina R, Castañeda-González JP, Montoya L, Gómez-Gómez MP, Clavijo Cabezas D, Plazas Vargas M. Prevalence of oncogenic driver mutations in Hispanics/Latin patients with lung cancer. Systematic review meta-analysis. Lung Cancer (Amsterdam, Netherlands). 2023;185:107378. https://doi.org/10.1016/J.LUNGCAN.2023.107378 .
doi: 10.1016/J.LUNGCAN.2023.107378
pubmed: 37729688
Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, Yang ZY, Mao C, Tang JL. The Prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985–93. https://doi.org/10.18632/oncotarget.12587 .
doi: 10.18632/oncotarget.12587
pubmed: 27738317
pmcid: 5346692
Melosky B, Kambartel K, Häntschel M, Bennetts M, Nickens DJ, Brinkmann J, Kayser A, Moran M, Cappuzzo F. Worldwide prevalence of epidermal growth factor receptor mutations in non-small cell lung cancer: a meta-analysis. Mol Diagn Ther. 2022;26:7. https://doi.org/10.1007/S40291-021-00563-1 .
doi: 10.1007/S40291-021-00563-1
pubmed: 34813053
John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR Mutations in non-small-cell lung cancer: a systematic literature review of prevalence and clinical outcomes. Cancer Epidemiol. 2022;76:102080. https://doi.org/10.1016/J.CANEP.2021.102080 .
doi: 10.1016/J.CANEP.2021.102080
pubmed: 34922050
Castañeda-González JP, Chaves JJ, Parra-Medina R. Multiple Mutations in the EGFR gene in lung cancer: a systematic review. Transl Lung Cancer Res. 2022;11:2148–63. https://doi.org/10.21037/TLCR-22-235/COIF .
doi: 10.21037/TLCR-22-235/COIF
pubmed: 36386461
pmcid: 9641033
Kim EY, Cho EN, Park HS, Hong JY, Lim S, Youn JP, Hwang SY, Chang YS. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17:237–45. https://doi.org/10.1080/15384047.2016.1139235 .
doi: 10.1080/15384047.2016.1139235
pubmed: 26785607
pmcid: 4848002
Shi H, Seegobin K, Heng F, Zhou K, Chen R, Qin H, Manochakian R, Zhao Y, Lou Y. Genomic landscape of lung adenocarcinomas in different races. Front Oncol. 2022;12:946625. https://doi.org/10.3389/FONC.2022.946625/FULL .
doi: 10.3389/FONC.2022.946625/FULL
pubmed: 36248982
pmcid: 9557241
Fan L, Feng Y, Wan H, Shi G, Niu W. Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis. PLoS ONE. 2014;9:100866. https://doi.org/10.1371/JOURNAL.PONE.0100866 .
doi: 10.1371/JOURNAL.PONE.0100866
Lin HM, Wu Y, Yin Y, Niu H, Curran EA, Lovly CM, Humphries MJ. Real-world ALK testing trends in patients with advanced non–small-cell lung cancer in the United States. Clin Lung Cancer. 2023;24:e39–49. https://doi.org/10.1016/j.cllc.2022.09.010 .
doi: 10.1016/j.cllc.2022.09.010
pubmed: 36376172
Velazquez A, Olazagasti C, Duma N. P59.09 Landscape of targetable genomic alterations in Hispanic/Latinx patients with non-small cell lung cancers. J Thorac Oncol. 2021;16:S1150–1. https://doi.org/10.1016/j.jtho.2021.08.598 .
doi: 10.1016/j.jtho.2021.08.598
Andreis TF, Correa BS, Vianna FS, Leistner-Segal F, Siebert M, Leistner-Segal S, Hahn EC, Ulbrich JM, RRivero LF, De Oliveira FH, et al. Analysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the country. J Global Oncol. 2019;5:1–9. https://doi.org/10.1200/JGO.19.00174 .
doi: 10.1200/JGO.19.00174
Mascarenhas E, Gelatti AC, Araújo LH, Baldotto C, Mathias C, Zukin M, Werutsky G, Pacheco P, Gomes R, de Castro G, et al. Comprehensive genomic profiling of brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418). Thoracic Cancer. 2021;12:580–7. https://doi.org/10.1111/1759-7714.13777 .
doi: 10.1111/1759-7714.13777
pubmed: 33314759
Martin C, Cuello M, Barajas O, Recondo G, Aruachan S, Perroud H, Sena S, Bonilla C, Orlandi F, Berutti S, et al. Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol. 2022;16:6. https://doi.org/10.3892/MCO.2021.2439 .
doi: 10.3892/MCO.2021.2439
pubmed: 34881026
Hernández-Pedro N, Soca-Chafre G, Alaez-Versón C, Carrillo-Sánchez K, Avilés-Salas A, Vergara E, Arrieta O. Mutational profile by targeted next generation sequencing of non-small cell lung cancer in the Mexican population. Salud Publica Mex. 2019;61:308–17. https://doi.org/10.21149/10113 .
doi: 10.21149/10113
pubmed: 31276344
Zheng R, Yin Z, Alhatem A, Lyle D, You B, Jiang AS, Liu D, Jobbagy Z, Wang Q, Aisner S, et al. Epidemiologic features of NSCLC gene alterations in Hispanic patients from Puerto Rico. Cancers. 2020;12:1–12. https://doi.org/10.3390/CANCERS12123492 .
doi: 10.3390/CANCERS12123492
Raez LE, Santos ES, Mourafetis J, Kim AY, Hunis B, Sareli C, Castillero L, Velis E. P1.13 (also presented as PD2.01): lung cancer chromosomal aberrations and gene expression profiles of hispanics living in the US or Latin America are similar. J Thor Oncol. 2016;11:S187–8. https://doi.org/10.1016/j.jtho.2016.08.035 .
doi: 10.1016/j.jtho.2016.08.035
Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J, Wömpner C, Bitter E, Koleczko S, et al. Co-occurrence of targetable mutations in Non-Small Cell Lung Cancer (NSCLC) patients harboring MAP2K1 mutations. Lung Cancer. 2020;144:40–8. https://doi.org/10.1016/j.lungcan.2020.04.020 .
doi: 10.1016/j.lungcan.2020.04.020
pubmed: 32361034
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, et al. Response to MEK inhibitor therapy in MAP2K1 (MEK1) K57N non–small-cell lung cancer and genomic landscape of MAP2K1 mutations in non–small-cell lung cancer. JCO Precis Oncol. 2022;6:e2200382. https://doi.org/10.1200/PO.22.00382 .
doi: 10.1200/PO.22.00382
pubmed: 36455195
Smeltzer MP, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, Varella-Garcia M, Meadows Taylor M, Richeimer K, Wood K, Howell KE, et al. The international association for the study of lung cancer global survey on molecular testing in lung cancer. J Thorac Oncol. 2020;15:1434–48. https://doi.org/10.1016/j.jtho.2020.05.002 .
doi: 10.1016/j.jtho.2020.05.002
pubmed: 32445813
Rivas S, Armisén R. Non-small cell lung cancer in the era of precision medicine. Rev Méd Clín Las Condes. 2022;33:25–35. https://doi.org/10.1016/j.rmclc.2022.01.001 .
doi: 10.1016/j.rmclc.2022.01.001
Ríos JA, Marcelain K, Plaza-Parrochia F, Selman C, Bustamante E, Godoy JA, Labbé TP, García-Bloj B. Planificación sanitaria a partir de los datos ómicos: ¿es posible esta idea para Chile? [The contribution of omic sciences for the management of cancer in Chile]. Rev Med Chil. 2021;149:1657–63. https://doi.org/10.4067/S0034-98872021001101657 .
doi: 10.4067/S0034-98872021001101657
pubmed: 35735330
Alvarez-Gomez RM, De la Fuente-Hernandez MA, Herrera-Montalvo L, Hidalgo-Miranda A. Challenges of diagnostic genomics in Latin America. Curr Opin Genet Dev. 2021;66:101–9. https://doi.org/10.1016/J.GDE.2020.12.010 .
doi: 10.1016/J.GDE.2020.12.010
pubmed: 33517184
Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association between younger age and targetable genomic alterations and prognosis in non-small-cell lung cancer. JAMA Oncol. 2016;2:313–20. https://doi.org/10.1001/JAMAONCOL.2015.4482 .
doi: 10.1001/JAMAONCOL.2015.4482
pubmed: 26720421
pmcid: 4819418
Liu X, Jiang G, Sun X, Su G, Zhang X, Shen D, Yan N. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma. Front Oncol. 2023;13:1275575. https://doi.org/10.3389/FONC.2023.1275575 .
doi: 10.3389/FONC.2023.1275575
pubmed: 38023198
pmcid: 10646490
Couraud S, Zalcman G, Milleron B, Morin F, Souquet PJ. Lung Cancer in never smokers – a review. Eur J Cancer. 2012;48:1299–311. https://doi.org/10.1016/J.EJCA.2012.03.007 .
doi: 10.1016/J.EJCA.2012.03.007
pubmed: 22464348
Leffondré K, Abrahamowicz M, Xiao Y, Siemiatycki J. Modelling smoking history using a comprehensive smoking index: application to lung cancer. Stat Med. 2006;25:4132–46. https://doi.org/10.1002/sim.2680 .
doi: 10.1002/sim.2680
pubmed: 16998807
Sepulveda, G.; Blanco, A.; Freire, M.; Lizana, R.; Caceres-Molina, J.; Ampuero, D.; Perez, P.; Ramos, L.; Aren, O.; Chernilo, S.; et al. Molecular Characterization of Non-Small Cell Lung Cancer Tumors in Latin American Patients from Brazil, Chile and Peru Uncovers Novel Potentially Driver Mutations. medRxiv 2020, 2020.09.11.20171025, https://doi.org/10.1101/2020.09.11.20171025 .
Sepúlveda-Hermosilla G, Freire M, Blanco A, Cáceres J, Lizana R, Ramos L, Assar Cuevas R, Ampuero D, Aren O, Chernilo S, et al. Concordance analysis of ALK gene fusion detection methods in patients with non-small-cell lung cancer from Chile, Brazil, and Peru. J Mol Diagn. 2021;23:1127–37. https://doi.org/10.1016/j.jmoldx.2021.05.018 .
doi: 10.1016/j.jmoldx.2021.05.018
pubmed: 34186175